ReForm partners with MilliporeSigma on excipients for biologics
The two companies enter a licensing agreement to commercialize excipients used in biotherapeutics.
Archives for February 13, 2020
Catalent takes over Zumutor’s lead candidate manufacture
Under an agreement with Zumutor, Catalent Biologics initiates clinical manufacture of the latter’s lead candidate targeting solid tumors, ahead of FDA filing.